Shots: The approval is based on P-III CAPSTONE-1 study assessing Xofluza vs PBO or oseltamivir 75 mg (bid for 5days) in the US & Japan (N=1436) and P-II study in otherwise healthy people with the Flu P-III CAPSTONE-1 study results: (Xofluza vs PBO): reduction in flu symptoms by >1day (54 hrs vs 80 hrs); (Xofluza […]Read More
